查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1947950

依適應症、通路、最終用戶和劑型分類的醋酸去氨加壓素片市場－全球預測，2026-2032年

Desmopressin Acetate Tablets Market by Indication, Distribution Channel, End User, Formulation - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 184 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2025 年，醋酸去氨加壓素片劑市值為 4.2591 億美元，預計到 2026 年將成長至 4.4341 億美元，到 2032 年將達到 5.6435 億美元，複合年成長率為 4.10%。

關鍵市場統計數據
基準年 2025 4.2591億美元
預計年份：2026年 4.4341億美元
預測年份 2032 5.6435億美元
複合年成長率 (%) 4.10%

簡明臨床概述，重點在於醋酸去氨加壓素片的治療作用、法規環境以及以病人為中心的考量。

醋酸去氨加壓素片在內分泌治療和症狀治療的交叉領域中佔據獨特的地位，尤其適用於需要控制抗利尿作用的情況。該化合物的藥理特性使其在模擬血管加壓素活性的同時，具有更高的安全性和耐受性，因此效用治療多種疾病，從中樞性尿崩症到兒童夜間遺尿症。臨床醫生和護理團隊依靠其可預測的抗利尿作用來減少夜間多尿和體液流失，而藥學委員會在考慮其在治療方案中的地位時，會評估其耐受性、給藥便利性和長期依從性等因素。

配方創新、監管機構對上市後證據的重視、數位化輔助技術以及供應鏈可追溯性等變革正在重塑策略重點。

多種因素正在共同重塑醋酸去氨加壓素片的市場格局，改變相關人員評估機會和風險的框架。製劑科學和緩釋技術的進步重新引發了關於給藥便利性和安全性範圍的討論，同時，對病患報告結果的日益關注正促使評估標準從傳統的療效終點轉向包括依從性、生活品質和看護者負擔在內的指標。

2025年關稅變化和貿易政策轉變如何促使製造商和買家採用動態籌資策略、增強供應鏈韌性並重新設計採購流程

2025年實施的關稅和貿易政策調整為參與醋酸去氨加壓素片生產、分銷和採購的公司帶來了新的營運挑戰。進口關稅和歸類規則的變化影響了籌資策略，促使製造商重新評估供應商關係、區域製造地和庫存計劃，以降低成本和交貨期的波動。這些趨勢迫使採購部門重新評估其總到岸成本模型，並考慮近岸外包和供應商多元化，以降低跨境關稅波動的風險。

以細分市場為重點的洞察揭示了適應症、通路、終端用戶環境、劑量和製劑如何決定商業性和臨床策略。

細分市場層面的細微差別揭示了臨床需求、分銷複雜性和給藥策略之間的交集，從而影響產品定位和商業化重點。以適應症為基礎的市場調查（中樞性尿崩症、原發性夜遺尿症、續發性夜遺尿症）突顯了臨床路徑的差異：中樞性尿崩症、原發性夜遺尿症、繼發性夜遺尿症）突顯了臨床路徑的差異：中樞性尿崩症需要長期治療並密切進行內分泌管理；續發性夜遺尿症需要以小兒科為中心的間歇性干預和以家庭為中心的依性疾病而需要對多因進行性病例而接受診斷行為的潛在病例。

美洲、歐洲、中東和非洲以及亞太地區的區域趨勢正在影響市場准入、監管方式和區域性商業化策略。

區域趨勢對臨床實務模式、監管預期和供應鏈產生了重大影響，並在各主要區域形成了不同的策略要務。在美洲，支付方框架、基層醫療處方習慣以及完善的門診藥房基礎設施決定了醋酸去氨加壓素片的取得和使用方式。該地區的相關人員普遍重視循證指南的實施以及與電子健康記錄的整合，以便進行用藥依從性監測。

品牌藥產品組合、學名藥供應商、特藥製劑商和契約製造製造商的競爭格局和差異化路徑

醋酸去氨加壓素片在競爭格局中的地位並非由單一的創新巨頭主導，而是由藥物研發公司、學名藥供應商、特藥製劑商和契約製造商之間的相互作用決定。藥物研發公司的產品系列通常著重於臨床支援、風險管理專案和病患教育資源，以提高病患的長期治療遵從性和安全性監測。另一方面，學名藥生產商則在生產效率、供應可靠性和價格競爭力方面展開競爭，同時也投入資源準備證明生物等效性和品質一致性的監管文件。

切實可行的策略建議，重點在於配方創新、供應鏈韌性、通路專案支援、支付方合作以及數位化病患專案。

為了在醋酸去氨加壓素片市場佔據優勢，行業領導企業應追求臨床卓越性、供應穩定性和差異化的患者支持三者兼備。重要的是，應優先投資於配方改進，以解決依從性難題（例如，更便捷的給藥方式和更輕的監測負擔），同時透過系統的真實世界資料項目檢驗安全性。將研發工作與適應性監管策略結合，可以加快藥物上市進程，並促進核准後數據的收集，從而滿足監管機構和支付方的期望。

採用混合方法研究方法，結合深入的二手文獻綜述、有針對性的一手訪談、專家檢驗和嚴格的品管技術。

本報告的調查方法融合了結構化的二手研究、有針對性的一手研究以及嚴格的檢驗，以確保可靠的證據基礎和可操作的研究結果。二手研究包括對同行評審的臨床文獻、監管文件和治療指南的全面回顧，以及對藥物警戒報告框架和藥物專論的分析，以闡明藥物的安全性和臨床定位。這項基礎性工作建構了臨床和監管背景，為更深入的研究奠定了基礎。

透過全面概述指導策略決策，重點在於闡述臨床效用、製劑開發、監管嚴格性和供應鏈策略之間的相互作用。

總之，醋酸去氨加壓素片仍是需要精確控制抗利尿作用的疾病的重要臨床選擇。然而，隨著製劑技術的進步、監管的日益嚴格以及分銷管道的創新，其應用環境也在不斷變化。相關人員必須平衡臨床需求（例如有效控制夜間症狀和保障病人安全）與營運需求（例如穩健的採購、合規的生產和靈活的分銷模式）。這兩種需求促使人們需要製定整合策略，該策略應兼顧臨床差異化、患者體驗和供應鏈的穩健性。

目錄

第1章：序言

第2章調查方法

  • 研究設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查前提
  • 調查限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會地圖
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

8. 依適應症分類的醋酸去氨加壓素片市場

  • 中樞性尿崩症
  • 原發性夜間遺尿症
  • 次發性遺尿

9. 醋酸去氨加壓素片市場依通路分類

  • 線上
  • 離線

第10章 依最終用戶分類的醋酸去氨加壓素片市場

  • 診所
  • 居家照護
  • 醫院

第11章：醋酸去氨加壓素片市場（以劑型分類）

  • 立即生效
  • 緩釋製劑

第12章 各地區去氨加壓素醋酸鹽片劑市場

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第13章 醋酸去氨加壓素片市場（依組別分類）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第14章 各國去氨加壓素醋酸鹽片市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

15. 美國醋酸去氨加壓素片市場

第16章 中國醋酸去氨加壓素片市場

第17章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Accord Healthcare Ltd.
  • Amneal Pharmaceuticals, Inc.
  • Apotex Inc.
  • Aurobindo Pharma Limited
  • Cipla Limited
  • Dr. Reddy's Laboratories Ltd.
  • Endo International plc
  • Ferring Pharmaceuticals Inc.
  • Fresenius Kabi AG
  • Glenmark Pharmaceuticals Limited
  • Hikma Pharmaceuticals PLC
  • Lupin Limited
  • Mylan NV
  • Novartis AG
  • Pfizer Inc.
  • Sandoz International GmbH
  • Strides Pharma Science Limited
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • Zydus Lifesciences Limited
Product Code: MRR-4F7A6D4FB6A0

The Desmopressin Acetate Tablets Market was valued at USD 425.91 million in 2025 and is projected to grow to USD 443.41 million in 2026, with a CAGR of 4.10%, reaching USD 564.35 million by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 425.91 million
Estimated Year [2026] USD 443.41 million
Forecast Year [2032] USD 564.35 million
CAGR (%) 4.10%

A concise and clinically focused introduction to desmopressin acetate tablets highlighting their therapeutic role, regulatory context, and patient-centered considerations

Desmopressin acetate tablets occupy a distinct niche at the intersection of endocrine therapy and symptomatic management, particularly where antidiuretic control is required. The compound's pharmacologic profile, which mimics vasopressin activity with an improved safety and tolerability margin, underpins its continued relevance for conditions ranging from central diabetes insipidus to pediatric nocturnal enuresis. Clinicians and care teams rely on its predictable antidiuretic effect to reduce nocturnal polyuria and fluid loss, while formulary committees evaluate tolerability, ease of administration, and long-term adherence characteristics when positioning it within therapeutic pathways.

Against this clinical backdrop, payer and provider stakeholders are increasingly focused on stewardship, real-world safety surveillance, and comparative effectiveness versus nonpharmacologic and alternative pharmacologic approaches. At the same time, formulation evolution and patient-centric delivery options have elevated adherence considerations, shaping how prescribers and caregivers discuss treatment goals. Regulatory authorities emphasize robust post-market monitoring for antidiuretic agents, prompting manufacturers and supply-chain partners to invest in compliance infrastructure and pharmacovigilance capabilities.

Consequently, an introduction to desmopressin acetate tablets must account for clinical utility, regulatory context, and evolving expectations around patient experience. Understanding these interrelated dimensions creates a foundation for strategic decisions in development, commercialization, and clinical practice alignment.

Transformative shifts driven by formulation innovation, regulatory emphasis on post-market evidence, digital adjuncts, and supply-chain traceability reshaping strategic priorities

The landscape for desmopressin acetate tablets is being reshaped by several converging forces that reframe how stakeholders evaluate opportunity and risk. Advances in formulation science and controlled-release technologies have enabled renewed conversations about dosing convenience and safety margins, while an emphasis on patient-reported outcomes has shifted evaluation criteria beyond traditional efficacy endpoints to include adherence, quality of life, and caregiver burden.

Simultaneously, regulatory frameworks are evolving to demand richer post-authorization safety data, driving manufacturers to integrate real-world evidence strategies into clinical development and commercial planning. Digital health adjuncts, including adherence monitoring and telehealth follow-ups, are increasingly integrated into treatment paradigms, enabling providers to better manage fluid balance and mitigate hyponatremia risk through closer monitoring and data-driven titration.

On the supply side, pharmaceutical manufacturers and contract partners are responding to heightened requirements for supply-chain traceability and manufacturing flexibility. This is altering sourcing strategies for active pharmaceutical ingredients and excipients, as well as accelerating adoption of quality-by-design approaches. Together, these shifts are creating a more complex but also more opportunity-rich environment for innovators, generics players, and specialty pharmacies to differentiate via formulation, support services, and integrated care models.

How 2025 tariff changes and trade policy shifts have compelled dynamic sourcing strategies, supply-chain resilience, and procurement re-engineering for manufacturers and buyers

The imposition of tariffs and trade policy adjustments in 2025 has introduced new operational realities for companies involved in the production, distribution, and procurement of desmopressin acetate tablets. Changes in import duties and classification rules have had implications for sourcing strategies, with manufacturers revisiting supplier relationships, regional manufacturing footprints, and inventory planning to mitigate cost and timing variability. These developments have prompted procurement teams to re-evaluate total landed cost models and to consider nearshoring or diversification of supplier bases to reduce exposure to cross-border tariff volatility.

Consequently, supply-chain partners and contract manufacturing organizations have increased focus on value-engineering and on incremental process optimizations to preserve margin and ensure continuity. In parallel, downstream distributors and pharmacies are adapting purchasing cadence and inventory buffers to smooth the impact of episodic cost shifts and regulatory customs requirements. Health systems and formularies are responding by tightening evaluation windows for alternative suppliers and by emphasizing contractual flexibility that can accommodate policy-driven price perturbations.

Taken together, the tariff environment of 2025 underscores the need for dynamic sourcing strategies, closer collaboration between commercial and supply functions, and scenario-based contingency planning to maintain access and affordability for patients reliant on desmopressin acetate therapy.

Segment-focused insights revealing how indication, distribution channels, end-user settings, dosage strengths, and formulation types determine commercial and clinical approaches

Segment-level nuances reveal where clinical demand, distribution complexity, and dosing strategies intersect to influence product positioning and commercialization focus. Based on Indication, market study across Central Diabetes Insipidus, Primary Nocturnal Enuresis, and Secondary Nocturnal Enuresis highlights divergent clinical pathways: central diabetes insipidus requires chronic management with close endocrine oversight, whereas primary nocturnal enuresis often involves episodic pediatric-focused interventions and family-centered adherence considerations, and secondary nocturnal enuresis demands investigation of underlying comorbidities and multidisciplinary care coordination.

Based on Distribution Channel, examination of Hospital Pharmacy, Online Pharmacy, and Retail Pharmacy demonstrates how channel-specific dynamics shape access and patient experience; hospital pharmacies are oriented toward inpatient and specialty prescribing, online pharmacies offer convenience and subscription models that support long-term adherence, and retail pharmacies provide immediate fulfillment and points of counseling. Based on End User, segmentation into Clinics, Homecare, and Hospitals surfaces distinct utilization patterns: clinics and outpatient practices emphasize follow-up and titration protocols, homecare contexts prioritize ease of dosing and caregiver education, and hospital settings focus on acute management and safety monitoring.

Based on Dosage Strength, study across 0.1 Mg, 0.2 Mg, and 0.4 Mg informs dosing strategy development and packaging configurations that align with titration pathways and age- or weight-based regimens. Based on Formulation, differentiation between Immediate Release and Sustained Release captures trade-offs between onset of action and duration, with implications for nocturnal symptom control, dosing frequency, and risk mitigation efforts.

Regional dynamics across the Americas, Europe Middle East & Africa, and Asia-Pacific that shape access, regulatory approaches, and localized commercialization tactics

Regional dynamics materially affect clinical practice patterns, regulatory expectations, and supply arrangements, creating differentiated strategic imperatives across major geographies. In the Americas, payer frameworks, primary care prescribing habits, and a robust outpatient pharmacy infrastructure shape how desmopressin acetate tablets are accessed and administered; stakeholders in this region commonly emphasize evidence-based guideline alignment and integration with electronic health records for adherence monitoring.

In Europe, Middle East & Africa, heterogeneous regulatory environments, variable reimbursement mechanisms, and distribution complexities require tailored regional strategies that account for country-level pricing policies, import controls, and differing clinical care models. Manufacturers and distributors often adopt segmented launch plans and targeted education initiatives to address the diversity of stakeholders and to ensure consistent pharmacovigilance practices across jurisdictions.

In Asia-Pacific, rapid urbanization, expanding private healthcare delivery, and increasing investment in specialty pharmaceuticals are influencing uptake patterns. Regional supply-chain hubs and manufacturing capacity expansions are also prominent, and strategic partnerships with local providers and distributors play a pivotal role in market access. Across all regions, local clinical guidelines, caregiver expectations, and health technology assessment processes must be navigated to ensure appropriate use and equitable patient access.

How originator portfolios, generic suppliers, specialty formulators, and contract manufacturers create a competitive ecosystem and differentiation pathways

Competitive positioning in the desmopressin acetate tablet landscape is defined less by a single dominant innovator and more by the interplay between originator formulations, generics suppliers, specialty formulators, and contract manufacturing providers. Innovator product portfolios typically emphasize clinical support, risk-management programs, and patient education resources that reinforce long-term therapy adherence and safety surveillance. Generics manufacturers, by contrast, compete on manufacturing efficiency, supply reliability, and price competitiveness while also investing in regulatory dossiers that demonstrate bioequivalence and consistent quality.

Specialty formulators and technology partners differentiate through extended-release platforms, novel excipient systems, and patient-friendly packaging that streamlines home administration. Contract manufacturing organizations and CDMOs play a strategic role by enabling capacity scale-up, offering flexible multi-source manufacturing, and implementing advanced quality systems to meet regional regulatory expectations. Service-oriented players, including specialty pharmacies and digital health vendors, further augment competitive dynamics by bundling adherence support, remote monitoring, and patient education into value propositions aimed at providers and payers.

Collectively, these company archetypes create a competitive ecosystem in which collaboration across development, manufacturing, and patient-support functions can be a critical source of differentiation and resilience.

Actionable strategic recommendations focused on formulation innovation, supply resiliency, channel-specific support, payer engagement, and digital-enabled patient programs

Industry leaders seeking to optimize their position in the desmopressin acetate tablets space should pursue a combination of clinical excellence, supply resiliency, and differentiated patient support. Prioritize investment in formulation refinements that address adherence challenges, such as dosing convenience and decreased monitoring burden, while simultaneously validating safety through structured real-world evidence programs. Aligning development efforts with adaptive regulatory strategies will help accelerate access pathways and facilitate post-authorization data collection that meets regulator and payer expectations.

Operationally, diversify supplier networks and consider regional manufacturing or tolling arrangements to reduce exposure to trade-policy shocks and tariff-driven cost variability. Strengthen relationships across distribution channels by deploying channel-specific support programs-hospital-oriented clinical liaisons, online pharmacy subscription models, and retail pharmacist education-to ensure consistent messaging and adherence reinforcement. Collaborate with payers and health systems to design value-based arrangements or outcomes-linked programs that reflect real-world benefits and patient-centric outcomes.

Finally, embed digital tools into patient support ecosystems to enable adherence monitoring, remote titration guidance, and timely safety surveillance. By integrating clinical, operational, and commercial levers, leaders can build resilient programs that respond to evolving regulatory demands and shifting care delivery preferences.

A mixed-methods research approach combining thorough secondary review, targeted primary interviews, expert validation, and robust quality-control practices

The report's methodology blends structured secondary research with targeted primary engagement and rigorous validation to ensure a robust evidence base and actionable insights. Secondary research encompasses comprehensive review of peer-reviewed clinical literature, regulatory documents, and therapeutic guidelines, supplemented by analysis of pharmacovigilance reporting frameworks and drug monographs to characterize safety and clinical positioning. This foundational work establishes the clinical and regulatory context upon which more granular inquiries are built.

Primary research includes interviews with clinicians, pharmacy directors, procurement experts, and patient advocacy representatives to surface real-world practice patterns, unmet needs, and adoption barriers. These qualitative inputs are triangulated with input from supply-chain and manufacturing specialists to capture operational constraints and sourcing preferences. Data validation steps involve cross-referencing primary insights with independent secondary sources and running iterative expert review panels to reconcile divergent perspectives and ensure interpretative rigor.

Throughout, quality control mechanisms-such as transparent documentation of data sources, audit trails for interview synthesis, and standardized templates for evidence grading-support reproducibility and credibility. This mixed-methods approach ensures that findings are grounded in both clinical realities and commercial pragmatism, enabling stakeholders to translate evidence into strategy.

Concluding synthesis emphasizing the interplay of clinical utility, formulation development, regulatory rigor, and supply-chain strategies to guide strategic decision-making

In conclusion, desmopressin acetate tablets remain a clinically important option for conditions that require precise antidiuretic control, while the broader environment around their use is evolving through formulation advances, regulatory rigor, and channel innovation. Stakeholders must balance clinical imperatives-such as effective nocturnal symptom control and patient safety-with operational necessities like resilient sourcing, compliant manufacturing, and adaptive distribution models. These dual imperatives drive the need for integrated strategies that account for clinical differentiation, patient experience, and supply-chain robustness.

Moving forward, organizations that invest in evidence generation, patient-centric delivery, and collaborative supply arrangements will be better positioned to navigate regional complexities and policy shifts. By combining clinical insight with operational discipline and targeted commercialization tactics, manufacturers and healthcare partners can improve patient outcomes while sustaining access and affordability. The synthesis of clinical, regulatory, and commercial perspectives presented here provides a practical foundation for decision-makers preparing to act in a dynamic therapeutic and policy landscape.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Desmopressin Acetate Tablets Market, by Indication

  • 8.1. Central Diabetes Insipidus
  • 8.2. Primary Nocturnal Enuresis
  • 8.3. Secondary Nocturnal Enuresis

9. Desmopressin Acetate Tablets Market, by Distribution Channel

  • 9.1. Online
  • 9.2. Offline

10. Desmopressin Acetate Tablets Market, by End User

  • 10.1. Clinics
  • 10.2. Homecare
  • 10.3. Hospitals

11. Desmopressin Acetate Tablets Market, by Formulation

  • 11.1. Immediate Release
  • 11.2. Sustained Release

12. Desmopressin Acetate Tablets Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Desmopressin Acetate Tablets Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Desmopressin Acetate Tablets Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States Desmopressin Acetate Tablets Market

16. China Desmopressin Acetate Tablets Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025
  • 17.5. Accord Healthcare Ltd.
  • 17.6. Amneal Pharmaceuticals, Inc.
  • 17.7. Apotex Inc.
  • 17.8. Aurobindo Pharma Limited
  • 17.9. Cipla Limited
  • 17.10. Dr. Reddy's Laboratories Ltd.
  • 17.11. Endo International plc
  • 17.12. Ferring Pharmaceuticals Inc.
  • 17.13. Fresenius Kabi AG
  • 17.14. Glenmark Pharmaceuticals Limited
  • 17.15. Hikma Pharmaceuticals PLC
  • 17.16. Lupin Limited
  • 17.17. Mylan N.V.
  • 17.18. Novartis AG
  • 17.19. Pfizer Inc.
  • 17.20. Sandoz International GmbH
  • 17.21. Strides Pharma Science Limited
  • 17.22. Sun Pharmaceutical Industries Ltd.
  • 17.23. Teva Pharmaceutical Industries Ltd.
  • 17.24. Zydus Lifesciences Limited

LIST OF FIGURES

  • FIGURE 1. GLOBAL DESMOPRESSIN ACETATE TABLETS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL DESMOPRESSIN ACETATE TABLETS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL DESMOPRESSIN ACETATE TABLETS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL DESMOPRESSIN ACETATE TABLETS MARKET SIZE, BY INDICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL DESMOPRESSIN ACETATE TABLETS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL DESMOPRESSIN ACETATE TABLETS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL DESMOPRESSIN ACETATE TABLETS MARKET SIZE, BY FORMULATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL DESMOPRESSIN ACETATE TABLETS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL DESMOPRESSIN ACETATE TABLETS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL DESMOPRESSIN ACETATE TABLETS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES DESMOPRESSIN ACETATE TABLETS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA DESMOPRESSIN ACETATE TABLETS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL DESMOPRESSIN ACETATE TABLETS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL DESMOPRESSIN ACETATE TABLETS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL DESMOPRESSIN ACETATE TABLETS MARKET SIZE, BY CENTRAL DIABETES INSIPIDUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL DESMOPRESSIN ACETATE TABLETS MARKET SIZE, BY CENTRAL DIABETES INSIPIDUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL DESMOPRESSIN ACETATE TABLETS MARKET SIZE, BY CENTRAL DIABETES INSIPIDUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL DESMOPRESSIN ACETATE TABLETS MARKET SIZE, BY PRIMARY NOCTURNAL ENURESIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL DESMOPRESSIN ACETATE TABLETS MARKET SIZE, BY PRIMARY NOCTURNAL ENURESIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL DESMOPRESSIN ACETATE TABLETS MARKET SIZE, BY PRIMARY NOCTURNAL ENURESIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL DESMOPRESSIN ACETATE TABLETS MARKET SIZE, BY SECONDARY NOCTURNAL ENURESIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL DESMOPRESSIN ACETATE TABLETS MARKET SIZE, BY SECONDARY NOCTURNAL ENURESIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL DESMOPRESSIN ACETATE TABLETS MARKET SIZE, BY SECONDARY NOCTURNAL ENURESIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL DESMOPRESSIN ACETATE TABLETS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL DESMOPRESSIN ACETATE TABLETS MARKET SIZE, BY ONLINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL DESMOPRESSIN ACETATE TABLETS MARKET SIZE, BY ONLINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL DESMOPRESSIN ACETATE TABLETS MARKET SIZE, BY ONLINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL DESMOPRESSIN ACETATE TABLETS MARKET SIZE, BY OFFLINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL DESMOPRESSIN ACETATE TABLETS MARKET SIZE, BY OFFLINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL DESMOPRESSIN ACETATE TABLETS MARKET SIZE, BY OFFLINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL DESMOPRESSIN ACETATE TABLETS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL DESMOPRESSIN ACETATE TABLETS MARKET SIZE, BY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL DESMOPRESSIN ACETATE TABLETS MARKET SIZE, BY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL DESMOPRESSIN ACETATE TABLETS MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL DESMOPRESSIN ACETATE TABLETS MARKET SIZE, BY HOMECARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL DESMOPRESSIN ACETATE TABLETS MARKET SIZE, BY HOMECARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL DESMOPRESSIN ACETATE TABLETS MARKET SIZE, BY HOMECARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL DESMOPRESSIN ACETATE TABLETS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL DESMOPRESSIN ACETATE TABLETS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL DESMOPRESSIN ACETATE TABLETS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL DESMOPRESSIN ACETATE TABLETS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL DESMOPRESSIN ACETATE TABLETS MARKET SIZE, BY IMMEDIATE RELEASE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL DESMOPRESSIN ACETATE TABLETS MARKET SIZE, BY IMMEDIATE RELEASE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL DESMOPRESSIN ACETATE TABLETS MARKET SIZE, BY IMMEDIATE RELEASE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL DESMOPRESSIN ACETATE TABLETS MARKET SIZE, BY SUSTAINED RELEASE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL DESMOPRESSIN ACETATE TABLETS MARKET SIZE, BY SUSTAINED RELEASE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL DESMOPRESSIN ACETATE TABLETS MARKET SIZE, BY SUSTAINED RELEASE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL DESMOPRESSIN ACETATE TABLETS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. AMERICAS DESMOPRESSIN ACETATE TABLETS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 38. AMERICAS DESMOPRESSIN ACETATE TABLETS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 39. AMERICAS DESMOPRESSIN ACETATE TABLETS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 40. AMERICAS DESMOPRESSIN ACETATE TABLETS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 41. AMERICAS DESMOPRESSIN ACETATE TABLETS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 42. NORTH AMERICA DESMOPRESSIN ACETATE TABLETS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. NORTH AMERICA DESMOPRESSIN ACETATE TABLETS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 44. NORTH AMERICA DESMOPRESSIN ACETATE TABLETS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 45. NORTH AMERICA DESMOPRESSIN ACETATE TABLETS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 46. NORTH AMERICA DESMOPRESSIN ACETATE TABLETS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 47. LATIN AMERICA DESMOPRESSIN ACETATE TABLETS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 48. LATIN AMERICA DESMOPRESSIN ACETATE TABLETS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 49. LATIN AMERICA DESMOPRESSIN ACETATE TABLETS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 50. LATIN AMERICA DESMOPRESSIN ACETATE TABLETS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 51. LATIN AMERICA DESMOPRESSIN ACETATE TABLETS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 52. EUROPE, MIDDLE EAST & AFRICA DESMOPRESSIN ACETATE TABLETS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 53. EUROPE, MIDDLE EAST & AFRICA DESMOPRESSIN ACETATE TABLETS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 54. EUROPE, MIDDLE EAST & AFRICA DESMOPRESSIN ACETATE TABLETS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 55. EUROPE, MIDDLE EAST & AFRICA DESMOPRESSIN ACETATE TABLETS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 56. EUROPE, MIDDLE EAST & AFRICA DESMOPRESSIN ACETATE TABLETS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 57. EUROPE DESMOPRESSIN ACETATE TABLETS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 58. EUROPE DESMOPRESSIN ACETATE TABLETS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 59. EUROPE DESMOPRESSIN ACETATE TABLETS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 60. EUROPE DESMOPRESSIN ACETATE TABLETS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 61. EUROPE DESMOPRESSIN ACETATE TABLETS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 62. MIDDLE EAST DESMOPRESSIN ACETATE TABLETS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. MIDDLE EAST DESMOPRESSIN ACETATE TABLETS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 64. MIDDLE EAST DESMOPRESSIN ACETATE TABLETS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 65. MIDDLE EAST DESMOPRESSIN ACETATE TABLETS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 66. MIDDLE EAST DESMOPRESSIN ACETATE TABLETS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 67. AFRICA DESMOPRESSIN ACETATE TABLETS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 68. AFRICA DESMOPRESSIN ACETATE TABLETS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 69. AFRICA DESMOPRESSIN ACETATE TABLETS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 70. AFRICA DESMOPRESSIN ACETATE TABLETS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 71. AFRICA DESMOPRESSIN ACETATE TABLETS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 72. ASIA-PACIFIC DESMOPRESSIN ACETATE TABLETS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 73. ASIA-PACIFIC DESMOPRESSIN ACETATE TABLETS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 74. ASIA-PACIFIC DESMOPRESSIN ACETATE TABLETS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 75. ASIA-PACIFIC DESMOPRESSIN ACETATE TABLETS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 76. ASIA-PACIFIC DESMOPRESSIN ACETATE TABLETS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL DESMOPRESSIN ACETATE TABLETS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 78. ASEAN DESMOPRESSIN ACETATE TABLETS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 79. ASEAN DESMOPRESSIN ACETATE TABLETS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 80. ASEAN DESMOPRESSIN ACETATE TABLETS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 81. ASEAN DESMOPRESSIN ACETATE TABLETS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 82. ASEAN DESMOPRESSIN ACETATE TABLETS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 83. GCC DESMOPRESSIN ACETATE TABLETS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 84. GCC DESMOPRESSIN ACETATE TABLETS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 85. GCC DESMOPRESSIN ACETATE TABLETS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 86. GCC DESMOPRESSIN ACETATE TABLETS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 87. GCC DESMOPRESSIN ACETATE TABLETS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 88. EUROPEAN UNION DESMOPRESSIN ACETATE TABLETS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 89. EUROPEAN UNION DESMOPRESSIN ACETATE TABLETS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 90. EUROPEAN UNION DESMOPRESSIN ACETATE TABLETS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 91. EUROPEAN UNION DESMOPRESSIN ACETATE TABLETS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 92. EUROPEAN UNION DESMOPRESSIN ACETATE TABLETS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 93. BRICS DESMOPRESSIN ACETATE TABLETS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 94. BRICS DESMOPRESSIN ACETATE TABLETS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 95. BRICS DESMOPRESSIN ACETATE TABLETS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 96. BRICS DESMOPRESSIN ACETATE TABLETS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 97. BRICS DESMOPRESSIN ACETATE TABLETS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 98. G7 DESMOPRESSIN ACETATE TABLETS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 99. G7 DESMOPRESSIN ACETATE TABLETS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 100. G7 DESMOPRESSIN ACETATE TABLETS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 101. G7 DESMOPRESSIN ACETATE TABLETS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 102. G7 DESMOPRESSIN ACETATE TABLETS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 103. NATO DESMOPRESSIN ACETATE TABLETS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 104. NATO DESMOPRESSIN ACETATE TABLETS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 105. NATO DESMOPRESSIN ACETATE TABLETS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 106. NATO DESMOPRESSIN ACETATE TABLETS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 107. NATO DESMOPRESSIN ACETATE TABLETS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL DESMOPRESSIN ACETATE TABLETS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 109. UNITED STATES DESMOPRESSIN ACETATE TABLETS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 110. UNITED STATES DESMOPRESSIN ACETATE TABLETS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 111. UNITED STATES DESMOPRESSIN ACETATE TABLETS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 112. UNITED STATES DESMOPRESSIN ACETATE TABLETS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 113. UNITED STATES DESMOPRESSIN ACETATE TABLETS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 114. CHINA DESMOPRESSIN ACETATE TABLETS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 115. CHINA DESMOPRESSIN ACETATE TABLETS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 116. CHINA DESMOPRESSIN ACETATE TABLETS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 117. CHINA DESMOPRESSIN ACETATE TABLETS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 118. CHINA DESMOPRESSIN ACETATE TABLETS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)